Pasithea Therapeutics (Pasithea Therapeutics) Cash-to-Debt : 199.16 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pasithea Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 199.16.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pasithea Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pasithea Therapeutics's Cash-to-Debt or its related term are showing as below:

KTTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 65.65 Med: 5099.58 Max: No Debt
Current: 199.16

During the past 4 years, Pasithea Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 65.65. And the median was 5099.58.

KTTA's Cash-to-Debt is ranked better than
82.54% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs KTTA: 199.16

Pasithea Therapeutics Cash-to-Debt Historical Data

The historical data trend for Pasithea Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pasithea Therapeutics Cash-to-Debt Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

65.65

199.16

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial									65.65	41.03	47.67	50.87	199.16

Competitive Comparison of Pasithea Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Pasithea Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pasithea Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Cash-to-Debt falls into.

Pasithea Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pasithea Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	16.331	/	(0.082	+	0)
	=	199.16

Pasithea Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	16.331	/	(0.082	+	0)
	=	199.16

Pasithea Therapeutics (NAS:KTTA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pasithea Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.

Executives

Graeme Martin Currie	officer: Chief Development Officer	51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a	10 percent owner	C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd.	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian	other: Member of 10% owner group	350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp	other: Member of 10% owner group	CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc	other: Member of 10% owner group	1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977